Trial Profile
Phase I/II trial of CA 18C3 in patients with advanced cancer, including haematological malignancies, in Switzerland.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2011
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- 14 Mar 2011 New trial record